17 research outputs found
L-Arginine promotes gut hormone release and reduces food intake in rodents
Aims: To investigate the anorectic effect of Lâarginine (LâArg) in rodents.
Methods: We investigated the effects of LâArg on food intake, and the role of the anorectic gut hormones glucagonâlike peptideâ1 (GLPâ1) and peptide YY (PYY), the Gâproteinâcoupled receptor family C group 6 member A (GPRC6A) and the vagus nerve in mediating these effects in rodents.
Results: Oral gavage of LâArg reduced food intake in rodents, and chronically reduced cumulative food intake in dietâinduced obese mice. Lack of the GPRC6A in mice and subdiaphragmatic vagal deafferentation in rats did not influence these anorectic effects. LâArg stimulated GLPâ1 and PYY release in vitro and in vivo. Pharmacological blockade of GLPâ1 and PYY receptors did not influence the anorectic effect of LâArg. LâArgâmediated PYY release modulated net ion transport across the gut mucosa. Intracerebroventricular (i.c.v.) and intraperitoneal (i.p.) administration of LâArg suppressed food intake in rats.
Conclusions: LâArg reduced food intake and stimulated gut hormone release in rodents. The anorectic effect of LâArg is unlikely to be mediated by GLPâ1 and PYY, does not require GPRC6A signalling and is not mediated via the vagus. I.c.v. and i.p. administration of LâArg suppressed food intake in rats, suggesting that LâArg may act on the brain to influence food intake. Further work is required to determine the mechanisms by which LâArg suppresses food intake and its utility in the treatment of obesity
Lâarginine promotes gut hormone release and reduces food intake in rodents
Aims: To investigate the anorectic effect of Lâarginine (LâArg) in rodents. Methods: We investigated the effects of LâArg on food intake, and the role of the anorectic gut hormones glucagonâlike peptideâ1 (GLPâ1) and peptide YY (PYY), the Gâproteinâcoupled receptor family C group 6 member A (GPRC6A) and the vagus nerve in mediating these effects in rodents. Results: Oral gavage of LâArg reduced food intake in rodents, and chronically reduced cumulative food intake in dietâinduced obese mice. Lack of the GPRC6A in mice and subdiaphragmatic vagal deafferentation in rats did not influence these anorectic effects. LâArg stimulated GLPâ1 and PYY release in vitro and in vivo. Pharmacological blockade of GLPâ1 and PYY receptors did not influence the anorectic effect of LâArg. LâArgâmediated PYY release modulated net ion transport across the gut mucosa. Intracerebroventricular (i.c.v.) and intraperitoneal (i.p.) administration of LâArg suppressed food intake in rats. Conclusions: LâArg reduced food intake and stimulated gut hormone release in rodents. The anorectic effect of LâArg is unlikely to be mediated by GLPâ1 and PYY, does not require GPRC6A signalling and is not mediated via the vagus. I.c.v. and i.p. administration of LâArg suppressed food intake in rats, suggesting that LâArg may act on the brain to influence food intake. Further work is required to determine the mechanisms by which LâArg suppresses food intake and its utility in the treatment of obesity
L-cysteine suppresses ghrelin and reduces appetite in rodents and humans
BACKGROUND: High-protein diets promote weight loss and subsequent weight maintenance, but are difficult to adhere to. The mechanisms by which protein exerts these effects remain unclear. However, the amino acids produced by protein digestion may have a role in driving protein-induced satiety. METHODS: We tested the effects of a range of amino acids on food intake in rodents and identified l-cysteine as the most anorexigenic. Using rodents we further studied the effect of l-cysteine on food intake, behaviour and energy expenditure. We proceeded to investigate its effect on neuronal activation in the hypothalamus and brainstem before investigating its effect on gastric emptying and gut hormone release. The effect of l-cysteine on appetite scores and gut hormone release was then investigated in humans. RESULTS: l-Cysteine dose-dependently decreased food intake in both rats and mice following oral gavage and intraperitoneal administration. This effect did not appear to be secondary to behavioural or aversive side effects. l-Cysteine increased neuronal activation in the area postrema and delayed gastric emptying. It suppressed plasma acyl ghrelin levels and did not reduce food intake in transgenic ghrelin-overexpressing mice. Repeated l-cysteine administration decreased food intake in rats and obese mice. l-Cysteine reduced hunger and plasma acyl ghrelin levels in humans. CONCLUSIONS: Further work is required to determine the chronic effect of l-cysteine in rodents and humans on appetite and body weight, and whether l-cysteine contributes towards protein-induced satiety
Surgical Mouse Models of Vertical Sleeve Gastrectomy and Roux-en Y Gastric Bypass: a Review
L-phenylalanine modulates gut hormone release and glucose tolerance, and suppresses food intake through the calcium sensing receptor in rodents
Objectives: High protein diets are associated with greater satiety and weight loss than diets rich in other macronutrients. The exact mechanisms by which high protein diets exert their effects are unclear. However, evidence suggests that the sensing of amino acids produced as a result of protein digestion may play a role in appetite regulation and satiety. We investigated the effects of L-phenylalanine (L-Phe) on food intake and glucose homeostasis in rodents. Methods: We investigated the effects of the aromatic amino acid and calcium sensing receptor (CaSR) agonist L-phenylalanine (L-Phe) on food intake and the release of the gastrointestinal hormones peptide YY (PYY), glucagon-like peptide-1 (GLP-1) and ghrelin in rodents, and the role of the CaSR in mediating these effects in vitro and in vivo. We also examined the effect of oral L-Phe administration on glucose tolerance in rats. Results: Oral administration of L-Phe acutely reduced food intake in rats and mice, and chronically reduced food intake and body weight in diet-induced obese mice. Ileal L-Phe also reduced food intake in rats. L-Phe stimulated GLP-1 and PYY release, and reduced plasma ghrelin, and also stimulated insulin release and improved glucose tolerance in rats. Pharmacological blockade of the CaSR attenuated the anorectic effect of intra-ileal L-Phe in rats, and L-Phe-induced GLP-1 release from STC-1 and primary L cells was attenuated by CaSR blockade. Conclusions: L-Phe reduced food intake, stimulated GLP-1 and PYY release and reduced plasma ghrelin in rodents. Our data provides evidence that the anorectic effects of L-Phe are mediated via the CaSR, and suggest that L-Phe and the CaSR system in the gastrointestinal tract may have therapeutic utility in the treatment of obesity and diabetes. Further work is required to determine the physiological role of the CaSR in protein sensing in the gut, and the role of this system in humans